Kedcyla 160mg Injection (Trastuzumab)

Kedcyla 160mg Injection is a prescription medication primarily used to treat HER2-positive breast cancer, particularly in cases where the cancer has spread to other parts of the body or has not responded to previous treatments. The active ingredient in Kedcyla is ado-trastuzumab emtansine, which combines the targeting capability of trastuzumab (an antibody that binds to HER2 receptors) with the cytotoxic effects of emtansine, a chemotherapy agent that destroys cancer cells.

Yes, you can buy Kedcyla 160mg Injection from Jasmeds, which is a reliable provider of wellness medicines in Pakistan offering 24/7 delivery service.

In the event of an overdose of Kadcyla (ado-trastuzumab emtansine) 160mg Injection, the following steps should be taken:

Contact Poison Control: Immediately reach out to your regional poison control center for guidance on managing the overdose.

Monitor Symptoms: Patients should be closely monitored for any adverse effects, as overdose can lead to serious complications such as thrombocytopenia (low platelet count) and other severe reactions.

No Antidote Available: Be aware that there is no known antidote for Kadcyla overdose, so management will focus on supportive care and monitoring.

Seek Medical Attention: If symptoms develop or if there is any uncertainty regarding the overdose, seek medical attention promptly to ensure appropriate care.

Yes, Kadcyla (ado-trastuzumab emtansine) 160mg Injection can be used in patients with kidney impairment, but there are important considerations:

No dose adjustment is recommended for patients with mild or moderate renal impairment. Patients can generally receive Kadcyla without changes to the standard dosing regimen.

No, It is advisable not to drive or operate machinery until you are sure that you can do so safely.